Professor Trent Woodruff
Professor

Trent Woodruff

Email: 
Phone: 
+61 7 336 52924

Background

Dr Woodruff is a Professor of Pharmacology who leads a research team aiming to find new therapeutic treatments for neurodegenerative disorders. Current therapies for these diseases are vastly inadequate, and so new research is needed to identify novel targets to slow or halt their progression. Prof Woodruff’s specific research revolves around the innate immune system in the brain, and the role of neuroinflammation in propagating disease. A key focus of his current work is testing new drugs developed at the University of Queensland in models of motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson's disease, as well as maintaining an active interest in acute inflammatory disorders including sepsis and ischemia-reperfusion injuries. Using a series of potent and orally active complement C5a and NLRP3 inflammasome inhibitors developed at UQ, Prof Woodruff's team has demonstrated the therapeutic potential of targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of these neurodegenerative diseases. His team has recently shown that in addition to their roles in neurodegeneration, innate immune factors also play essential roles in stem and neuronal cell development during embryogenesis, revealing the widespread physiological and pathological roles of this evolutionarily ancient immune system.

Availability

Professor Trent Woodruff is:
Available for supervision
Media expert

Fields of research

Immunology Neurosciences Pharmacology and pharmaceutical sciences

Qualifications

  • Bachelor (Honours) of Science (Advanced), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Neurodegenerative disease

    Studying new treatments to halt disease progression

  • Parkinson's disease

    Studying new treatments to halt disease progression

  • Motor neuron disease

    Studying new treatments to halt disease progression

Search Professor Trent Woodruff’s works on UQ eSpace

316 works between 2000 and 2025
All (316) Journal Article (235) Book Chapter (10) Conference Publication (70) Other Outputs (1)

281 - 300 of 316 works

2008

Conference Publication

Blockade of C5a receptors reduces astroglial inflammation in a rat SOD1G93A model of amyotrophic lateral sclerosis

Woodruff, Trent, Denny, Kerina, Crane, James, Atkin, Julie, Taylor, Steve and Noakes, Peter (2008). Blockade of C5a receptors reduces astroglial inflammation in a rat SOD1G93A model of amyotrophic lateral sclerosis. ICW Basel, XXII International Complement Workshop, Basel, Switzerland, 28 September-02 October 2008. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/j.molimm.2008.08.202

Blockade of C5a receptors reduces astroglial inflammation in a rat SOD1G93A model of amyotrophic lateral sclerosis

2008

Journal Article

Targeting ischemic brain injury with intravenous immunoglobulin

Arumugam, Thiruma V., Selvaraj, Pradeep K., Woodruff, Trent M. and Mattson, Mark P. (2008). Targeting ischemic brain injury with intravenous immunoglobulin. Expert Opinion on Therapeutic Targets, 12 (1), 19-29. doi: 10.1517/14728222.12.1.19

Targeting ischemic brain injury with intravenous immunoglobulin

2008

Conference Publication

Novel Haemodynamic effects of recombinant C5a and C5a des Arg in rats and mice

Moore, Tyson, Woodruff, Trent, Manthey, Helga, Monk, Peter, Taylor, Stephen and Shiels, Ian (2008). Novel Haemodynamic effects of recombinant C5a and C5a des Arg in rats and mice. ICW Basel, XXII International Complement Workshop, Basel, Switzerland, 28 September-2 October 2008. Oxford, United Kingdom: Elseiver. doi: 10.1016/j.molimm.2008.08.165

Novel Haemodynamic effects of recombinant C5a and C5a des Arg in rats and mice

2008

Conference Publication

Role of complement in motor neuron disease: Animal models and therapeutic potential of complement inhibitors

Woodruff, Trent R., Costantini, Kerina J., Taylor, Steve M. and Noakes, Peter G. (2008). Role of complement in motor neuron disease: Animal models and therapeutic potential of complement inhibitors. 4th Aegean Workshop on Complement Associated Diseases, Animal Models and Therapeutics, Porto Heli, Greece, 10-17 June 2007. New York, United States: Springer New York LLC. doi: 10.1007/978-0-387-78952-1_11

Role of complement in motor neuron disease: Animal models and therapeutic potential of complement inhibitors

2008

Conference Publication

Protective effects of C5a receptor antagonism in a mouse model of atherosclerosis

Manthey, Helga, Thomas, Anita, Taylor, Stephen, Woodruff, Trent, Moore, Tyson, Shiels, Ian and Rolfe, Barbara (2008). Protective effects of C5a receptor antagonism in a mouse model of atherosclerosis. ICW Basel, XXII International Complement Workshop, Basel, Switzerland, 28 September - 2 October 2008. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.molimm.2008.08.167

Protective effects of C5a receptor antagonism in a mouse model of atherosclerosis

2008

Conference Publication

Chronic complement-mediated inflammation promotes recovery after spinal cord injury

Beck, K. D., Nguyen, H. X., Woodruff, T. M. and Anderson, A. J. (2008). Chronic complement-mediated inflammation promotes recovery after spinal cord injury. American Society for Neurochemistry 39th Annual Meeting, San Antonio, United States, 1-5 March 2008. Chichester, West Sussex, United Kingom: Wiley-Blackwell. doi: 10.1111/j.1471-4159.2008.05160.x

Chronic complement-mediated inflammation promotes recovery after spinal cord injury

2007

Journal Article

The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding

Scola, A. M., Higginbottom, A., Partridge, L, J., Reid, R. C., Woodruff, T., Taylor, S. M., Fairlie, D. P. and Monk, P. N. (2007). The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding. Journal of Biological Chemistry, 282 (6), 3664-3671. doi: 10.1074/jbc.M609178200

The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding

2006

Journal Article

Complement mediators in ischemia-reperfusion injury

Arumugam, Thiruma V., Magnus, Tim, Woodruff, Trent M., Proctor, Lavinia M., Shiels, Ian A., Taylor, Stephen M., A. H. Wu and J. Delanghe (2006). Complement mediators in ischemia-reperfusion injury. Clinica Chimica Acta, 374 (1-2), 33-45. doi: 10.1016/j.cca.2006.06.010

Complement mediators in ischemia-reperfusion injury

2006

Journal Article

Transdermal pharmacology of small molecule cyclic C5a antagonists

Proctor, Lavinia M, Woodruff, Trent M, Sharma, Prakirti, Shiels, Ian A and Taylor, Stephen M (2006). Transdermal pharmacology of small molecule cyclic C5a antagonists. Advances in experimental medicine and biology, 586, 329-345.

Transdermal pharmacology of small molecule cyclic C5a antagonists

2006

Journal Article

Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats

Proctor, Lavinia M., Strachan, Anna J., Woodruff, Trent M., Mahadevan, Indumathy B., Williams, H. Ming, Shiels, Ian A. and Taylor, Stephen M. (2006). Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. International Immunopharmacology, 6 (8), 1224-1232. doi: 10.1016/j.intimp.2006.03.002

Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats

2006

Journal Article

Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration

Woodruff, Trent M., Crane, James W., Proctor, Lavinia. M., Buller, Kathryn M., Shek, Annie B., De Vos, Kurt, Pollitt, Sandra, Williams, Hua M., Shiels, Ian A., Monk, Peter N. and Taylor, Stephen M. (2006). Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB Journal, 20 (9), 1407-1417. doi: 10.1096/fj.05-5814com

Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration

2006

Journal Article

Recent developments in C5/C5a inhibitors

Proctor, Lavinia M., Woodruff, Trent M. and Taylor, Stephen M. (2006). Recent developments in C5/C5a inhibitors. Expert Opinion On Therapeutic Patents, 16 (4), 445-458. doi: 10.1517/13543776.16.4.445

Recent developments in C5/C5a inhibitors

2006

Journal Article

Complement factor 5a as a therapeutic target

Woodruff, T.M., Proctor, L.M., Strachan, A.J. and Taylor, S.M. (2006). Complement factor 5a as a therapeutic target. Drugs of The Future, 31 (4), 325-334. doi: 10.1358/dof.2006.031.04.980656

Complement factor 5a as a therapeutic target

2006

Book Chapter

Transdermal Pharmacology of Small Molecule Cyclic C5a Antagonists

Proctor, Lavinia M., Woodruff, Trent M., Sharma, Prakirti, Shiels, Ian A., Taylor, Stephen M. and Lambris, John D. (2006). Transdermal Pharmacology of Small Molecule Cyclic C5a Antagonists. Current Topics in Complement. (pp. 329-345) edited by John D. Lambris. New York: Springer. doi: 10.1007/0-387-34134-X_22

Transdermal Pharmacology of Small Molecule Cyclic C5a Antagonists

2005

Journal Article

Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site

Higginbottom, Adrian, Cain, Stuart A., Woodruff, Trent M., Proctor, Lavinia M., Madala, Praveen K., Tyndall, Joel D. A., Taylor, Stephen M., Fairlie, David P. and Monk, Peter N. (2005). Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. Journal of Biological Chemistry, 280 (18), 17831-17840. doi: 10.1074/jbc.M410797200

Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site

2005

Journal Article

A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis

Woodruff, Trent M., Arumugam, Thiruma V., Shiels, Ian A., Newman, Michelle L., Ross, Paul A., Reid, Robert C., Fairlie, David P. and Taylor, Stephen M. (2005). A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. International Immunopharmacology, 5 (5), 883-892. doi: 10.1016/j.intimp.2005.01.003

A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis

2005

Journal Article

Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease

Woodruff, T. M., Pollitt, S., Proctor, L. M., Stocks, S. Z., Manthey, H. D., Williams, H. M., Mahadevan, I. B., Shiels, I. A. and Taylor, S. M. (2005). Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. Journal of Pharmacology And Experimental Therapeutics, 314 (2), 811-817. doi: 10.1124/jpet.105.086835

Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease

2004

Journal Article

Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats

Arumugam, Thiruma V., Woodruff, Trent M., Stocks, Shelli Z., Proctor, Lavinia M., Pollitt, Sandra, Shiels, Ian A., Reid, Robert C., Fairlie, David P., Taylor, Stephen M. and M. Colombo (2004). Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. Journal of Hepatology, 40 (6), 934-941. doi: 10.1016/j.jhep.2004.02.017

Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats

2004

Journal Article

Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats

Arumugam, Thiruma V., Woodruff, Trent M., Stocks, Shelli Z., Proctor, Lavinia M., Pollitt, Sandra, Shiels, Ian A., Reid, Robert C., Fairlie, David P. and Taylor, Stephen M. (2004). Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. Journal of Hepatology, 40 (6), 934-941. doi: 10.1016/S0168-8278(04)00066-2

Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats

2004

Journal Article

The role of the complement system in ischemia-reperfusion injury

Arumugam, Thiruma V., Shiels, Ian A., Woodruff, Trent M., Granger, D. Neil and Taylor, Stephen M. (2004). The role of the complement system in ischemia-reperfusion injury. Shock, 21 (5), 401-409. doi: 10.1097/01.shk.0000121227.73012.86

The role of the complement system in ischemia-reperfusion injury

Current funding

  • 2024 - 2027
    Preclinical development of complement C5a receptor 2 modulators for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2024 - 2025
    Examining the efficacy of monepantel in the 6-OHDA model of Parkinson's disease
    PharmAust Limited
    Open grant
  • 2024 - 2025
    Investigating the pharmacological activity of monepantel on autophagy in the NSC-34 motor neuron cell line
    PharmAust Limited
    Open grant
  • 2024 - 2026
    Developing novel peptide tracers for improving immunotherapy outcomes
    NHMRC Development Grant
    Open grant
  • 2022 - 2025
    Therapeutic Inhibition of Neutrophil Activity as a Disease-Modifying Treatment for Amyotrophic Lateral Sclerosis
    United States Congressionally Directed Medical Research Programs - Amyotrophic Lateral Sclerosis Research Program
    Open grant
  • 2022 - 2025
    Making peptides orally bioavailable
    ARC Discovery Projects
    Open grant
  • 2022 - 2026
    Developing new therapies targeting innate immune mediated inflammation in neurodegenerative disease
    NHMRC Investigator Grants
    Open grant

Past funding

  • 2023 - 2024
    Therapeutic potential of targeting one of the core players of inflammation (Inflammasome) in MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2024
    C9orf72 dipeptide-mediated activation of microglia as a therapeutic target for MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2024
    Inhibiting complement C5a receptors to improve heart function in type 2 diabetes (DARP Grant administered by Monash University
    Monash University
    Open grant
  • 2022 - 2024
    Profiling monocytes in MND to assess disease progression and heterogeneity
    Cure for MND Foundation - Impact Grants
    Open grant
  • 2022 - 2023
    An integrated analytical network for protein characterisation
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2022 - 2024
    Developing FXIIa inhibitors as next-generation anticoagulants
    NHMRC Development Grant
    Open grant
  • 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND
    Motor Neurone Disease Research Institute of Australia Inc Linda Rynalski Bridge Funding Grant
    Open grant
  • 2021 - 2023
    Complement C5aR1: A novel therapeutic target for brain cancer
    Brain Cancer Innovation Project Grants
    Open grant
  • 2021 - 2023
    Targeting complement C5a receptor 2 as a disease-modifying treatment for motor neuron disease
    NHMRC Development Grant
    Open grant
  • 2020 - 2021
    Inflammatory biomarkers in 6-OHDA mouse model of Parkinson's disease
    UniQuest Pty Ltd
    Open grant
  • 2020 - 2024
    Preclinical development of centrally active complement C3a receptor modulators as disease-modifying drugs for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2020 - 2022
    Investigating the PROfile of complement activation in relation to Vasospasm, delayed cerebral Ischaemia and aneurysmal Subarachnoid haemorrhage Outcomes (ProcVISO Study) (administered by RBWH)
    Metro North Hospital and Health Service
    Open grant
  • 2020 - 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND.
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Investigating the therapeutic inhibition of CXCR2 as a disease modifying treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2022
    Eph receptor blockade to prevent and repair endothelial damage in systemic inflammation
    The Children's Hospital Foundation
    Open grant
  • 2019 - 2020
    Investigating the beneficial effects of complement C3aR on immune cell glucose metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Manipulation of free fatty acid receptors to tame the immune response in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019
    A versatile accurate mass, high resolution QTOF mass spectrometer for chemistry and proteomic applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019
    Advanced Brightfield and Fluorescent High Speed and Throughput Slide Scanner for biological, medical, materials science, and agricultural applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019 - 2023
    Harnessing the Innate Immune System to Target Cancer: A Novel Immunotherapeutic Strategy for Solid Tumours
    NHMRC Development Grant
    Open grant
  • 2019 - 2020
    Role of NLRP3 inflammasome activation in the prognosis of secondary progressive multiple sclerosis
    Metro North Hospital and Health Service
    Open grant
  • 2019 - 2022
    Understanding the mechanism of action for intravenous immunoglobulin (IVIG) therapy in spinal cord injury
    NHMRC Project Grant
    Open grant
  • 2018 - 2019
    Targeting peripheral inflammatory pathology in Parkinson's disease using repurposed drugs
    Wesley Medical Research Ltd
    Open grant
  • 2018 - 2019
    Therapeutic inhibition of the terminal complement pathway as a disease-modifying treatment for motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Therapeutic testing of the clinical candidate drug PMX205 in a TDP43-based model of MND and its mechanism
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2020
    Therapeutic potential of inhibiting Eph/ephrin signalling to repair the vascular endothelium in septic shock
    NHMRC Project Grant
    Open grant
  • 2018 - 2022
    Validating the NLRP3 Inflammasome as a Therapeutic Target in Motor Neuron Disease
    NHMRC Project Grant
    Open grant
  • 2017 - 2018
    A potential role for C5a antagonism in the medical management of feline hypertrophic cardiornyopathy
    Peter & Mary Ellen Stone Memorial Fund
    Open grant
  • 2017 - 2019
    Defining inflammatory biomarkers in motor neuron disease patients to assist in clinical trial efficiency of the C5aR antagonist PMX205
    Wesley Medical Research Ltd
    Open grant
  • 2017 - 2020
    New Treatments for Brain Disease
    Queensland Government Advance Queensland Innovation Partnerships
    Open grant
  • 2017 - 2023
    The Queensland Drug Repurposing Initiative
    Queensland Government Advance Queensland Innovation Partnerships
    Open grant
  • 2017 - 2019
    Is there a potential therapeutic role for Eph/ephrin signalling blockade in children with severe sepsis?
    Financial Markets Foundation for Children
    Open grant
  • 2017 - 2018
    Therapeutic inhibition of HMGB1 to slow disease progression in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    A Pharmacology Screening Facility to Accelerate Drug Discovery and Development
    UQ Major Equipment and Infrastructure
    Open grant
  • 2017 - 2021
    Preclinical Development of Complement C5aR Antagonists for the Treatment of Motor Neuron Disease
    NHMRC Development Grant
    Open grant
  • 2016 - 2018
    Pharmacological Targeting of Proinflammatory Kinase Signalling in Parkinson's disease
    The Michael J Fox Foundation for Parkinsons Research
    Open grant
  • 2016 - 2020
    Blocking inflammasome-induced neuroinflammation in PD with a potent, orally available small molecule
    The Michael J Fox Foundation Therapeutic Pipeline Program
    Open grant
  • 2016 - 2018
    Is there a potential therapeutic role for Eph/ephrin signalling blockade in patients with septic shock?
    Bayer Pharma AG
    Open grant
  • 2016 - 2017
    Development of complement C5aR1 antagonists for the treatment of motor neuron disease
    UQ Collaboration and Industry Engagement Fund - FirstLink
    Open grant
  • 2016 - 2017
    Exploiting the opposing actions of complement receptors C3aR and C5aR1 in the treatment of MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2016 - 2020
    Therapeutic targeting of neuroinflammation to slow the progression of neurodegenerative disease
    NHMRC Career Development Fellowship
    Open grant
  • 2016
    Exosome and Bio/Nanoparticle Characterisation Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016 - 2018
    Targeting the Complement Cascade: A Novel Therapeutic Strategy for Metastatic Melanoma
    NHMRC Project Grant
    Open grant
  • 2015 - 2017
    Pharmacological targeting of the NLRP3 inflammasome in pre-clinical models of Parkinson's disease using a potent orally active inhibitor
    The Michael J Fox Foundation for Parkinsons Research
    Open grant
  • 2015 - 2017
    Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease
    NHMRC Project Grant
    Open grant
  • 2015 - 2020
    Determining the contribution of peripheral immune complement signalling in the progression of motor neuron disease
    NHMRC Project Grant
    Open grant
  • 2015 - 2017
    Inhibitors of NLRP3 activation for treatment of inflammatory CNS diseases
    NHMRC Project Grant
    Open grant
  • 2015
    Therapeutic targeting of inflammation in Parkinson's disease
    RL Cooper Medical Research Foundation Limited
    Open grant
  • 2015 - 2016
    Therapeutic targeting of the NLRP3 inflammasome using a potent and orally active inhibitor in experimental MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014 - 2015
    Development of a rapid ex vivo screening assay for immunotoxicity of nanoparticles
    UQ Collaboration and Industry Engagement Fund - Seed Research Grant
    Open grant
  • 2014
    Innate immune complement signalling in peripheral immune cells during the progression of motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013
    Establishment of an Integrated Facility for Single Cell Analysis
    UQ Major Equipment and Infrastructure
    Open grant
  • 2012 - 2016
    Investigating the Role of the Innate Immune Complement System in the Abnormal Development of the Central Nervous System
    ARC Future Fellowships
    Open grant
  • 2012 - 2014
    Contribution of Complement C5a to Neuronal Cell Death during Ischemic Stroke
    NHMRC Project Grant
    Open grant
  • 2012
    Establishment of Integrated Small Animal Metabolic and Physiology Assessment Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011 - 2013
    Microdialysis to monitor fluid shifts and predict organ failure in the systemic inflammatory response syndrome
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2011
    A Multi-Channel Fluorescence Plate Reader for Studying Receptor-Ligand Interactions
    NHMRC Equipment Grant
    Open grant
  • 2011
    Building UQ's analytical capacity in biomedical sciences
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011
    Molecular Stereology Facility Upgrade
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011
    Real time regional tissue analysis suite
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011 - 2013
    The role of the innate immune system during the progression of motor neuron disease; the search for new therapeutic targets
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2011 - 2013
    Therapeutic Targeting of Complement C5a Receptors in Huntington's Disease
    NHMRC Project Grant
    Open grant
  • 2010 - 2012
    Therapeutic modulation of the innate immune complement system as a new and adjunct therapy to treat a wide variety of cancers
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2010 - 2013
    Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases
    ARC Linkage Projects
    Open grant
  • 2010 - 2012
    Complement activation in experimental epilepsy: role of C5a receptors
    NHMRC Project Grant
    Open grant
  • 2010
    In Situ Hybridization Suite for Biomedical Science Researchers
    NHMRC Equipment Grant
    Open grant
  • 2010 - 2011
    Notch-1 contributes to neuronal cell death and glial inflammation by modulating NFkappaB activity in ischaemic stroke
    National Heart Foundation of Australia
    Open grant
  • 2009 - 2011
    Characterizing novel therapeutic interventions in a new model of focal retinopathy
    NHMRC Project Grant
    Open grant
  • 2009 - 2013
    Complement C5a Receptors , Placental Inflammation and Reproductive Impairment.
    NHMRC Project Grant
    Open grant
  • 2009
    Liquid Scintillation Spectroscopy Facility
    UQ School/Centre Co-Funding
    Open grant
  • 2009
    Role of Complements Anaphylatoxin Receptors in Experimental Stroke
    UQ Early Career Researcher
    Open grant
  • 2008 - 2010
    Characterisation of the effect of C5a receptor antagonists against the C5a-like receptor 2 (C5L2)
    UQ New Staff Research Start-Up Fund
    Open grant
  • 2008 - 2010
    Establishment of therapeutically relevant animal models and markers for Crohn's Disease
    ARC Linkage Projects
    Open grant
  • 2008 - 2012
    NHMRC Career Development Award (Biomedical - Level 1): The role of the complement system in neurodegeneration and the therapeutic potential of complement inhibition
    NHMRC Career Development Award
    Open grant
  • 2008
    Role of the complement system in the healthy and diseased central nervous system
    ARC Discovery Projects
    Open grant
  • 2007 - 2008
    Scientific Visit - Protective actions of novel anti-inflammatory agents in neurotoxin-damaged neuronal cultures mimicking Parkinson's disease
    Australian Academy of Science
    Open grant
  • 2005
    The effectiveness of C5a receptor antagonists in the treatment of motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant

Availability

Professor Trent Woodruff is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Role of immune and inflammatory pathways in the progression of neurodegenerative disease

Supervision history

Current supervision

Completed supervision

Enquiries

Contact Professor Trent Woodruff directly for media enquiries about:

  • Drug Development
  • Huntington's disease
  • motor neuron disese
  • Neurodegenerative disease
  • Parkinson's disease

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au